Navigation Links
SkinMedica Announces Collaboration Agreement with Massachusetts General Hospital for Research and Development of Pigmentation Products
Date:8/30/2012

CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- SkinMedica, Inc., the fastest-growing skin care brand in the U.S., today announced that it will collaborate with Massachusetts General Hospital (MGH) for the research and development of pigmentation products.

(Logo: http://photos.prnewswire.com/prnh/20120612/NY23080LOGO)

The principal investigator for this collaborative effort is David Fisher, M.D., Ph.D., chief of the Massachusetts General Hospital Department of Dermatology, Director of the MGH Cutaneous Biology Research Center and Director of the Melanoma Center at MGH.  He is also the Edward Wigglesworth Professor of Dermatology at Harvard Medical School and past President of the Society for Melanoma Research, the largest international society dedicated to the study of melanoma.  SkinMedica and MGH have entered into an exclusive agreement to screen and evaluate a library of roughly 40,000 natural extracts made available by the National Cancer Institute for potential applications in pigmentation.

"We are delighted to have the opportunity to collaborate with Dr. Fisher, a world leader in dermatology research," said Mary Fisher, Chief Executive Officer of SkinMedica. "His expertise in pigment and the skin's environmental responses will be invaluable as we together pursue novel approaches for patients with a variety of pigment related concerns."

"With this collaboration, we can progress our screening work toward understanding the role of natural products in supporting or inhibiting the processes that generate pigment, and to identifying practical solutions for these patients," said Dr. Fisher.  "Hyperpigmentation is one of the most frequently cited concerns resulting in patient visits to a dermatologist, with the most common forms being melasma, solar lentigines and post-inflammatory hyperpigmentation."

About Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $750 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica's clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience, the newest division of SkinMedica, offers dermatologist-recommended, high-performance cosmetics formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment.

TNS Recovery Complex®, VANIQA®, Colorescience® and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.


'/>"/>
SOURCE SkinMedica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
4. Emergency Nurses Association Announces Corporate Sponsors for Annual Conference
5. Rosetta Genomics Announces Exercise and Closing of Underwriters Over-Allotment Option
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. Regeneron Announces September 2012 Investor Conference Presentations
8. Proacta Incorporated Announces IND Allowance for PR610
9. Tribogenics Announces Dual-Energy X-ray Source for XRF
10. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
11. Cynosure Announces Upcoming Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):